ArticleBlood advances2025

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

Sandra Castaño-Díez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.